Nifty
Sensex
:
:
11462.20
38095.07
35.35 (0.31%)
70.75 (0.19%)

Pharmaceuticals & Drugs

Rating :
76/99

BSE: 500302 | NSE: PEL

2639.40
-4.50 (-0.17%)
18-Mar-2019 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  2650.00
  •  2685.60
  •  2627.90
  •  2643.90
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  434508
  •  11468.40
  •  3307.95
  •  1794.90

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 48,753.33
  • 9.83
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 90,447.12
  • 0.95%
  • 1.79

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 49.99%
  • 1.80%
  • 11.66%
  • FII
  • DII
  • Others
  • 3.87%
  • 1.17%
  • 31.51%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.60
  • 18.75
  • 18.79

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 25.19
  • 52.02
  • 24.96

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 31.37
  • -
  • 89.58

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 10.29
  • 21.13
  • 28.55

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 1.43
  • 1.86
  • 2.30

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.11
  • 18.21
  • 16.28

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Net Sales
3,489.08
2,858.36
22.07%
3,144.10
2,535.86
23.99%
2,902.49
2,254.07
28.77%
2,991.06
2,462.64
21.46%
Expenses
1,461.80
1,410.98
3.60%
1,491.06
1,265.97
17.78%
1,375.82
1,192.26
15.40%
1,610.27
1,430.29
12.58%
EBITDA
2,027.28
1,447.38
40.07%
1,653.04
1,269.89
30.17%
1,526.67
1,061.81
43.78%
1,380.79
1,032.35
33.75%
EBIDTM
58.10%
50.64%
52.58%
50.08%
52.60%
47.11%
46.16%
41.92%
Other Income
102.80
63.79
61.15%
56.31
75.39
-25.31%
14.43
83.84
-82.79%
36.51
86.32
-57.70%
Interest
1,168.83
749.72
55.90%
1,016.18
724.71
40.22%
909.08
673.23
35.03%
830.64
589.72
40.85%
Depreciation
132.57
109.99
20.53%
123.36
129.33
-4.62%
128.79
122.91
4.78%
115.10
121.54
-5.30%
PBT
828.68
651.46
27.20%
569.81
491.24
15.99%
50.98
349.51
-85.41%
471.56
399.27
18.11%
Tax
293.04
211.79
38.36%
162.78
189.75
-14.21%
181.02
102.05
77.38%
-3,380.01
103.18
-
PAT
535.64
439.67
21.83%
407.03
301.49
35.01%
-130.04
247.46
-
3,851.57
296.09
1,200.81%
PATM
15.35%
15.38%
12.95%
11.89%
-4.48%
10.98%
128.77%
12.02%
EPS
32.93
28.24
16.61%
26.59
22.13
20.15%
-3.82
17.44
-
218.80
17.92
1,120.98%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
12,526.73
10,631.03
8,503.65
6,341.51
5,122.61
4,502.74
3,520.19
2,158.87
1,673.08
3,624.47
3,244.81
Net Sales Growth
23.89%
25.02%
34.10%
23.79%
13.77%
27.91%
63.06%
29.04%
-53.84%
11.70%
 
Cost Of Goods Sold
1,532.04
1,518.35
1,401.10
1,305.94
1,314.40
1,195.02
1,113.57
927.24
694.03
1,397.21
1,236.54
Gross Profit
10,994.69
9,112.68
7,102.55
5,035.57
3,808.21
3,307.72
2,406.62
1,231.63
979.05
2,227.26
2,008.27
GP Margin
87.77%
85.72%
83.52%
79.41%
74.34%
73.46%
68.37%
57.05%
58.52%
61.45%
61.89%
Total Expenditure
5,938.95
5,475.73
5,004.50
4,649.26
4,237.69
3,867.83
3,105.38
2,159.80
2,465.72
2,944.25
2,699.75
Power & Fuel Cost
-
106.48
101.03
98.73
92.15
89.35
82.12
65.82
59.82
79.26
81.07
% Of Sales
-
1.00%
1.19%
1.56%
1.80%
1.98%
2.33%
3.05%
3.58%
2.19%
2.50%
Employee Cost
-
1,988.14
1,793.87
1,683.05
1,294.76
1,136.95
796.53
436.42
411.65
573.32
488.37
% Of Sales
-
18.70%
21.10%
26.54%
25.28%
25.25%
22.63%
20.22%
24.60%
15.82%
15.05%
Manufacturing Exp.
-
552.87
506.60
514.80
583.17
557.39
520.26
317.34
145.94
186.33
210.20
% Of Sales
-
5.20%
5.96%
8.12%
11.38%
12.38%
14.78%
14.70%
8.72%
5.14%
6.48%
General & Admin Exp.
-
648.69
628.30
567.54
524.38
473.46
306.39
201.10
202.80
300.12
274.64
% Of Sales
-
6.10%
7.39%
8.95%
10.24%
10.51%
8.70%
9.32%
12.12%
8.28%
8.46%
Selling & Distn. Exp.
-
265.52
280.64
205.77
269.81
245.82
194.24
121.27
110.50
250.27
202.98
% Of Sales
-
2.50%
3.30%
3.24%
5.27%
5.46%
5.52%
5.62%
6.60%
6.91%
6.26%
Miscellaneous Exp.
-
395.68
292.96
273.43
159.02
169.84
92.27
90.61
840.98
157.74
202.98
% Of Sales
-
3.72%
3.45%
4.31%
3.10%
3.77%
2.62%
4.20%
50.27%
4.35%
6.35%
EBITDA
6,587.78
5,155.30
3,499.15
1,692.25
884.92
634.91
414.81
-0.93
-792.64
680.22
545.06
EBITDA Margin
52.59%
48.49%
41.15%
26.69%
17.27%
14.10%
11.78%
-0.04%
-47.38%
18.77%
16.80%
Other Income
210.05
264.10
233.75
251.66
254.75
225.43
196.17
472.23
1,317.52
152.92
158.27
Interest
3,924.73
2,978.30
2,030.98
974.08
510.60
1,049.58
575.01
215.46
88.83
183.81
198.40
Depreciation
499.82
477.33
381.70
255.45
289.87
246.90
209.56
129.29
95.86
142.65
119.57
PBT
1,921.03
1,963.77
1,320.22
714.38
339.20
-436.14
-173.59
126.55
340.19
506.68
385.36
Tax
-2,743.17
-2,876.42
228.12
49.51
344.96
62.75
24.76
5.63
3,679.71
18.03
21.94
Tax Rate
-142.80%
-146.47%
17.41%
6.51%
11.36%
-14.43%
-12.85%
4.66%
22.22%
3.61%
6.44%
PAT
4,664.20
4,841.40
1,082.43
710.53
2,690.68
-498.28
-223.06
111.50
12,883.36
481.90
316.25
PAT before Minority Interest
4,666.52
4,840.19
1,082.14
710.53
2,690.39
-497.52
-217.48
115.26
12,883.67
481.74
318.81
Minority Interest
2.32
1.21
0.29
0.00
0.29
-0.76
-5.58
-3.76
-0.31
0.16
-2.56
PAT Margin
37.23%
45.54%
12.73%
11.20%
52.53%
-11.07%
-6.34%
5.16%
770.04%
13.30%
9.75%
PAT Growth
263.05%
347.27%
52.34%
-73.59%
-
-
-
-99.13%
2,573.45%
52.38%
 
Unadjusted EPS
274.50
281.76
72.27
52.43
165.20
-29.10
-13.20
6.60
572.20
21.00
15.10

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
26,445.39
14,882.57
12,948.35
11,735.93
9,321.06
10,723.56
11,242.03
11,836.42
1,684.89
1,317.07
Share Capital
36.05
34.51
34.51
34.51
34.51
34.51
34.51
33.58
41.80
41.80
Total Reserves
26,409.34
14,848.06
12,913.84
11,701.42
9,286.55
10,689.05
11,207.52
11,802.84
1,643.09
1,275.27
Non-Current Liabilities
25,355.41
18,775.97
11,759.51
7,817.04
6,709.95
1,598.43
1,180.37
1,155.32
1,351.74
1,411.63
Secured Loans
23,420.22
11,714.16
3,099.39
1,539.08
504.42
609.44
208.81
232.25
575.36
451.66
Unsecured Loans
800.39
2,781.53
4,374.61
2,248.40
2,175.18
551.60
439.41
424.30
719.60
887.42
Long Term Provisions
5,144.43
4,689.03
4,497.72
4,048.77
4,026.55
346.63
346.81
258.89
0.00
0.00
Current Liabilities
22,478.73
18,962.28
10,542.27
5,694.05
9,490.09
11,764.78
6,111.55
4,693.23
1,041.96
1,070.46
Trade Payables
874.29
764.29
702.56
509.57
485.11
539.18
412.97
339.97
442.50
423.67
Other Current Liabilities
6,037.87
5,563.12
2,706.14
1,400.84
1,369.74
1,223.68
764.05
407.35
116.61
207.00
Short Term Borrowings
14,665.88
12,079.48
6,828.93
2,829.32
6,400.74
6,018.77
1,014.45
69.32
0.00
0.00
Short Term Provisions
900.69
555.39
304.64
954.32
1,234.50
3,983.15
3,920.08
3,876.59
482.85
439.79
Total Liabilities
74,291.53
52,634.03
35,250.25
25,276.13
25,521.10
24,098.57
18,544.29
17,690.73
4,078.59
3,806.61
Net Block
10,725.53
9,972.70
7,525.28
7,065.23
6,191.00
5,709.41
1,827.78
1,443.72
1,977.35
1,946.44
Gross Block
11,782.37
10,552.42
7,779.80
8,876.19
7,671.41
6,889.36
2,489.08
1,903.21
2,753.68
2,605.90
Accumulated Depreciation
1,056.84
579.72
254.52
1,810.96
1,480.41
1,179.95
661.30
459.49
776.33
659.46
Non Current Assets
61,725.87
43,470.62
30,595.31
19,911.89
21,149.44
16,397.63
13,307.38
8,036.06
2,145.56
2,066.92
Capital Work in Progress
647.18
879.63
355.02
277.14
491.07
371.96
260.77
138.45
135.66
92.65
Non Current Investment
23,526.62
21,716.66
15,682.30
6,820.88
9,249.93
6,969.82
6,577.86
380.86
32.55
27.83
Long Term Loans & Adv.
26,794.43
10,865.75
6,937.04
5,469.79
5,000.80
1,109.37
441.64
269.44
0.00
0.00
Other Non Current Assets
32.11
35.88
95.67
278.85
216.64
2,237.07
4,199.33
5,803.59
0.00
0.00
Current Assets
12,565.66
9,163.41
4,654.94
5,364.24
4,371.66
7,700.94
5,236.91
9,654.67
1,933.03
1,739.69
Current Investments
5,198.53
3,463.95
634.40
947.01
195.85
906.94
386.22
1,100.72
0.00
0.00
Inventories
774.02
723.07
723.77
674.94
652.30
541.82
465.60
382.56
469.45
483.36
Sundry Debtors
1,355.45
1,107.74
970.81
831.73
719.77
597.57
436.65
374.74
437.61
486.63
Cash & Bank
2,467.01
1,540.90
365.94
460.08
333.60
287.52
57.82
1,770.26
41.18
94.55
Other Current Assets
2,770.65
250.69
155.37
75.63
2,470.14
5,367.09
3,890.62
6,026.39
984.79
675.15
Short Term Loans & Adv.
2,518.77
2,077.06
1,804.65
2,374.85
1,636.43
4,048.46
3,785.30
4,114.27
976.93
665.13
Net Current Assets
-9,913.07
-9,798.87
-5,887.33
-329.81
-5,118.43
-4,063.84
-874.64
4,961.44
891.07
669.23
Total Assets
74,291.53
52,634.03
35,250.25
25,276.13
25,521.10
24,098.57
18,544.29
17,690.73
4,078.59
3,806.61

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
-15,966.59
-10,056.65
-6,956.19
-2,206.85
-1,604.43
-1,570.46
-684.78
-4,537.14
432.92
372.77
PBT
1,963.77
1,310.26
714.38
339.20
-436.14
-173.59
120.89
16,414.55
499.77
340.75
Adjustment
1,285.23
812.70
679.55
342.03
1,092.38
632.39
-140.32
-16,451.69
279.28
248.30
Changes in Working Capital
-18,374.37
-11,723.56
-7,977.81
-2,495.18
-2,132.96
-1,880.13
-585.24
-314.67
-231.56
-85.31
Cash after chg. in Working capital
-15,125.37
-9,600.60
-6,583.88
-1,813.95
-1,476.72
-1,421.33
-604.67
-351.81
547.49
503.74
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-841.22
-456.05
-329.63
-344.27
-125.70
-130.00
-74.45
-3,540.60
-107.66
-86.36
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
-42.68
-48.63
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,767.73
-2,402.84
-604.04
6,177.07
1,482.91
-1,664.46
-1,581.80
9,157.64
-157.46
-377.12
Net Fixed Assets
-350.07
-713.28
387.94
4.99
-74.35
-89.52
-357.29
614.10
-146.67
-289.09
Net Investments
-6,456.37
779.61
-7,831.14
1,363.48
-1,963.06
-2,512.81
-5,527.04
-1,390.60
-62.67
-1.72
Others
5,038.71
-2,469.17
6,839.16
4,808.60
3,520.32
937.87
4,302.53
9,934.14
51.88
-86.31
Cash from Financing Activity
18,650.25
13,570.46
7,543.90
-3,864.63
125.84
3,280.68
640.17
-2,984.62
-313.57
-9.75
Net Cash Inflow / Outflow
915.93
1,110.97
-16.33
105.59
4.32
45.76
-1,626.41
1,635.88
-38.11
-14.10
Opening Cash & Equivalents
1,364.21
226.57
233.35
325.18
268.65
52.98
1,678.88
38.12
94.55
55.10
Closing Cash & Equivalent
2,300.64
1,364.21
226.57
447.01
325.18
268.65
52.98
1,678.88
41.18
94.55

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
1467.15
857.49
746.05
676.19
537.05
617.86
647.74
700.87
80.15
62.65
ROA
7.63%
2.46%
2.35%
10.59%
-2.01%
-1.02%
0.64%
118.37%
12.22%
9.84%
ROE
23.42%
7.78%
5.76%
25.55%
-4.96%
-1.98%
1.00%
190.57%
32.10%
26.46%
ROCE
8.53%
8.96%
7.19%
18.70%
3.30%
2.41%
2.60%
213.86%
24.26%
24.15%
Fixed Asset Turnover
0.95
0.93
0.77
0.62
0.62
0.76
0.99
0.72
1.37
1.54
Receivable days
42.25
44.38
51.55
54.96
53.08
53.19
67.98
88.00
45.82
51.38
Inventory Days
25.68
30.89
40.00
47.02
48.12
51.81
71.06
92.29
47.24
48.86
Payable days
60.32
59.62
53.66
46.87
53.98
57.39
67.88
92.24
58.77
60.19
Cash Conversion Cycle
7.62
15.66
37.89
55.11
47.22
47.60
71.16
88.05
34.29
40.05
Total Debt/Equity
1.67
2.05
1.26
0.62
1.02
0.72
0.18
0.06
0.77
1.02
Interest Cover
1.66
1.65
1.78
6.94
0.59
0.66
1.56
187.46
3.72
2.72

Annual Reports:

News Update:


  • Piramal Enterprises’ partner launches generic cinacalcet hydrochloride tablets in US
    12th Mar 2019, 14:38 PM

    Piramal’s subsidiary, Piramal Healthcare has partnered with Slate Run with the goal of developing a non-infringing formulation of cinacalcet hydrochloride tablets

    Read More
  • Piramal Enterprises’ business unit launches MITIGO in US market
    12th Mar 2019, 09:44 AM

    MITIGO is an opioid agonist, for use in continuous microinfusion devices indicated only for intrathecal or epidural infusion

    Read More
  • CARE assigns ‘A1+’ rating to Piramal Enterprises’ NCDs
    8th Mar 2019, 10:22 AM

    The agency has assigned rating to the company’s NCDs worth Rs 500 crore

    Read More
  • Supreme Court exempts Piramal Enterprises’ Saridon from List of Banned FDCs
    21st Feb 2019, 14:05 PM

    In September 2018, PEL had been awarded a stay order from the Supreme Court on the ban, which allowed it to continue manufacturing, distribution and sale of the FDC

    Read More
  • Piramal Enterprises, Ivanhoe Cambridge invest Rs 500 crore in Lodha's Palava City
    5th Feb 2019, 14:25 PM

    Piramal Enterprises had earlier set up a strategic co-investment fund with Ivanhoe Cambridge to provide long term equity capital to blue chip residential developers

    Read More
  • Piramal Enterprises reports 23% rise in Q3 consolidated net profit
    28th Jan 2019, 14:29 PM

    Total consolidated income of the company increased by 22.92% at Rs 3,591.88 crore for Q3FY19

    Read More
  • Piramal Enterprises - Quarterly Results
    28th Jan 2019, 13:20 PM

    Read More
  • Piramal Enterprises raises Rs 5,000 crore via bonds in last one month
    14th Jan 2019, 10:37 AM

    Piramal Capital & Housing Finance also raised Rs 4,000 crore of term loans in the same period

    Read More
  • Piramal Enterprises gets nod to raise funds via MLDs
    3rd Jan 2019, 11:43 AM

    The Administrative Committee of the Board of Directors of the Company at their meeting held on January 02, 2019, consider the same

    Read More
  • Piramal Enterprises planning to raise funds up to Rs 100 crore via MLDs
    31st Dec 2018, 11:16 AM

    The meeting of the Administrative Committee of the Board of Directors of the Company will be held on January 02, 2019, to consider the same

    Read More
  • Piramal Enterprises’ arm launches new home loan product
    27th Dec 2018, 10:30 AM

    This product is specially designed for parent-child where both can together pay a higher EMI in the initial years

    Read More
  • Piramal Enterprise to raise funds on private placement
    27th Dec 2018, 10:18 AM

    The Non-Convertible Bonds are proposed to be listed on Wholesale Debt Market segment of NSE

    Read More
  • Piramal Enterprises planning to raise up to Rs 2,650 crore via NCDs
    22nd Dec 2018, 09:50 AM

    The NCDs are proposed to be listed in the wholesale debt market segment of the NSE

    Read More
  • Piramal Enterprises planning to raise fund via NCDs
    19th Dec 2018, 10:10 AM

    The Administrative Committee of the Company at its meeting to be held on December 21, 2018, to consider the same

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.